The clearer BENEFITS of belatacept

New England Journal of Medicine

Volumn 374, Issue 4, 2016, Pages 388-389

  Heher, Eliot ^a   Markmann, James F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

GRAFT SURVIVAL; HUMAN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

ABATACEPT; CYCLOSPORINE; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 84955471175     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1515765     Document Type: Editorial

References (8)

1. United States Renal Data System. 2015 USRDS annual data report: epidemiology of kidney disease in the United States. 2015 (http://www.usrds.org/2015/view/v2-07.aspx).
2. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016;374:333-43.
3. Ingelfinger JR, Schwartz RS. Immunosuppression - the promise of specificity. N Engl J Med 2005;353:836-9.
4. Leibler C, Matignon M, Pilon C, et al. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells. Am J Transplant 2014;14:1173-82.
5. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant 2014;14:59-69.
6. Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant 2014;14:1142-51.
7. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007;7:1722-32.
8. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562-75.